Health Care·Biotechnology·$7.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.12 | N/A | +7.69% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.12 | N/A | +7.69% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future revenue streams. They emphasized the importance of partnerships in achieving long-term goals.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on strategic partnerships to drive future growth.
Halozyme's earnings report shows a mixed picture, with a slight EPS beat but no revenue figures available. The stock fell 1.41% likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's ability to generate revenue moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ESSENT GROUP LTD
May 8, 2015